| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2575920 | The American Journal of Geriatric Pharmacotherapy | 2009 | 12 Pages |
Abstract
Conclusions: The definitive survival advantage of irinotecan observed in clinical trials was not reproducible in this population of elderly Medicare patients. The results emphasize the need for expansion of trials to include a more diverse patient group as well as continued evaluation of more recent chemotherapies in real-world settings.
Related Topics
Health Sciences
Medicine and Dentistry
Geriatrics and Gerontology
Authors
Nour A. PhD, Françoise G. PhD, Ilene H. PhD, Sylvain MD, MBA, C. Daniel PhD,